Search

Madrigal Pharmaceuticals Inc

Geschlossen

BrancheGesundheitswesen

516.57 -0.04

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

513

Max

519.94

Schlüsselkennzahlen

By Trading Economics

Einkommen

36M

-58M

Verkäufe

53M

364M

EPS

-1.99

Gewinnspanne

-15.906

Angestellte

915

EBITDA

30M

-56M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+33.35% upside

Dividenden

By Acuity

Nächstes Ergebnis

3. Nov. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-583M

12B

Vorheriger Eröffnungskurs

516.61

Vorheriger Schlusskurs

516.57

Nachrichtenstimmung

By Acuity

48%

52%

141 / 340 Ranking in Healthcare

Madrigal Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

21. Aug. 2026, 19:46 UTC

Madrigal Pharmaceuticals is lower in Friday's session, retracing from an earlier peak amid broader market pressures from rising Treasury yields and inflation concerns.

20. Aug. 2026, 23:46 UTC

Madrigal Pharmaceuticals shares are lower in after-market trading. Broader market declines are attributed to rising crude oil prices and geopolitical tensions.

18. Aug. 2026, 19:56 UTC

Madrigal Pharmaceuticals shares are lower today amid rising Treasury yields, which may be influencing investor sentiment. Earlier, the stock pulled back from a session high.

17. Aug. 2026, 19:35 UTC

Madrigal Pharmaceuticals is trading higher today, continuing gains since Friday's close, despite no specific company news driving the upward movement.

14. Aug. 2026, 19:26 UTC

Social Media

Madrigal Pharmaceuticals launches a Phase 2a study for resmetirom. Shares are lower today, pulled back from earlier gains amid broader market concerns over retail sales.

13. Aug. 2026, 21:01 UTC

Madrigal Pharmaceuticals Inc shares are higher in after-market trading, showing notable movement since Thursday's close, though no specific news explains the price action.

12. Aug. 2026, 21:01 UTC

Madrigal Pharmaceuticals shares are higher in after-market trading. Positive market sentiment follows comments on CPI reports that may impact Federal Reserve interest rate decisions.

10. Aug. 2026, 19:16 UTC

Madrigal Pharmaceuticals Inc shares are higher, despite no specific news. Broader market conditions reflect a decline in U.S. stock futures amid job data.

7. Aug. 2026, 20:02 UTC

Madrigal Pharmaceuticals shares are lower during Friday's session, continuing a decline since Thursday. The stock remains below its 20-day moving average.

6. Aug. 2026, 21:01 UTC

News

Madrigal Pharmaceuticals granted equity inducement awards to ten new employees, boosting shares modestly higher in after-market trading.

4. Aug. 2026, 20:04 UTC

Social Media
News

Madrigal Pharmaceuticals upgraded to Outperform by Wolfe Research, with a price target of $605. Shares are higher since Monday, despite a pullback earlier today.

3. Aug. 2026, 19:31 UTC

News
Social Media

Madrigal Pharmaceuticals shares are higher as CEO Bill Sibold notes market hesitance toward IVA due to weight gain concerns. The broader market also advances.

31. Juli 2026, 23:06 UTC

Madrigal Pharmaceuticals Inc shares are lower in after-market hours with no specific news identified. The stock remains near the lower end of its one-month range.

30. Juli 2026, 19:27 UTC

News

Madrigal Pharmaceuticals shares are lower following a widened second-quarter net loss of $57.9 million and increased operating expenses of $420.6 million.

29. Juli 2026, 22:26 UTC

Madrigal Pharmaceuticals shares are lower in after-market hours, reflecting broader market volatility following the Federal Reserve's interest rate decision and inflation concerns.

28. Juli 2026, 18:46 UTC

Madrigal Pharmaceuticals is lower today, continuing a broader decline since Monday's close. No specific news has been identified to explain the movement.

27. Juli 2026, 23:56 UTC

Madrigal Pharmaceuticals Inc is trading higher in after-market hours, reflecting a notable increase since Monday's close, despite no specific news identified.

20. Juli 2026, 16:02 UTC

Social Media

Madrigal Pharmaceuticals is lower today amid aggressive call buying and heightened market volume, with broader inflation concerns influenced by geopolitical tensions.

Peer-Vergleich

Kursveränderung

Madrigal Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

33.35% Vorteil

12-Monats-Prognose

Durchschnitt 689.08 USD  33.35%

Hoch 962 USD

Tief 543 USD

Basierend auf 13 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Madrigal Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

13 ratings

12

Buy

1

Halten

0

Sell

Stimmung

By Acuity

141 / 340 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
help-icon Live chat